Results 141 to 150 of about 4,843 (156)

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

Circulation, 2023
Miguel Angel Barba Romero, Carlos Guijarro, Paola Helena Ponte Márquez   +2 more
exaly  

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)

Kidney Medicine, 2022
Teodoro Bottiglieri, Ankit Mehta
exaly  

Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy, 2020
Anton Camaj, Michel Zeitouni
exaly  

ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand

Journal of Clinical Lipidology, 2020
Zhou-Qing Huang, Yaling Han, Zuyi Yuan
exaly  

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Diabetes Care, 2021
Margus Viigimaa, Thomas Knickelbine, Nakarin Sansanayudh   +2 more
exaly  

Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study

Atherosclerosis, 2021
Robert Pordy, Ori Yellin, Elane Van Nieuwenhuizen   +2 more
exaly  

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

Journal of the American College of Cardiology, 2019
Philippe Gabriel Steg, Harvey White, Shaun G Goodman   +2 more
exaly  

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

Journal of Clinical Lipidology, 2020
Eli M Roth, Jennifer G Robinson, Garen Manvelian   +2 more
exaly  

ODYSSEY MONO: Effect of Alirocumab 75 Mg Subcutaneously Every 2 Weeks As Monotherapy Versus Ezetimibe Over 24 Weeks

Future Cardiology, 2015
Eli M Roth, James M McKenney
exaly  

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.

European Heart Journal, 2016
Nandhini Sehar, Klaus Parhofer, Paul D. Thompson   +2 more
exaly